Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Implementing a center-wide precision medicine strategy at a major cancer center is a true multidisciplinary effort and requires comprehensive alignment of a broad screening strategy with a clinical research enterprise that can use these data to accelerate development of new treatments. Here, we describe the genomic screening approach at Memorial Sloan Kettering Cancer Center, a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology designated MSK-IMPACT, and how it enables and supports a large clinical trial portfolio enriched for multi-histology, biomarker-selected, ‘basket’ studies of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 1×
“For instance, somatic mutations in myeloidleukemia-associated genes have been associated with advanced age and could identify patients with a pre-leukemic state [15-17].”
BackgroundEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · cited 1×
“The therapeutic value of targeting oncogenic alterations responsible for the growth and metastasis of cancer has now been well established in a variety of clinical settings including human epidermal growth factor (HER2[s1])-positive breast cancer [1,2], BRAF mutant melanoma [3], lung cancers with alterations of epider…”
BackgroundCrizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 1×
“The therapeutic value of targeting oncogenic alterations responsible for the growth and metastasis of cancer has now been well established in a variety of clinical settings including human epidermal growth factor (HER2[s1])-positive breast cancer [1,2], BRAF mutant melanoma [3], lung cancers with alterations of epider…”
BackgroundPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Self-citationMemorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citation
Research works printed but not linked: 8
- Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 · DOI · Paper page
- Won, 2013, Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing, J. Vis. Exp., 80, e50710
- Cheng, 2015, MSK-IMPACT: a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology, J. Mol. Diagn.
- Zheng, 2014, Anchored multiplex PCR for targeted next-generation sequencing, Nat. Med., 20, 1479, 10.1038/nm.3729 · DOI · Paper page
- Wu, 2013, Identification of targetable FGFR gene fusions in diverse cancers, Cancer Discov., 3, 636, 10.1158/2159-8290.CD-13-0050 · DOI · Paper page
- Green, 2013, ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing, Genet. Med., 15, 565, 10.1038/gim.2013.73 · DOI · Paper page
- Catenacci, 2015, Tumor genome analysis includes germline genome: are we ready for surprises?, Int. J. Cancer, 136, 1559, 10.1002/ijc.29128 · DOI
- Paik, 2015, Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping, Cancer Discov., 5, 842, 10.1158/2159-8290.CD-14-1467 · DOI · Paper page
Cited by
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Self-citationMolecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
Pan-cancer integrative histology-genomic analysis via multimodal deep learning
Chen, R. J., Lu, M. Y., Williamson, D. F. K., Chen, T. Y., Lipkova, J., Noor, Z., Shaban, M., Shady, M., Williams, M., Joo, B., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.004 · Cited by 660
Abida, W., Armenia, J., Gopalan, A., Brennan, R., Walsh, M., Barron, D., Danila, D., Rathkopf, D., Morris, M., Slovin, S., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00029 · Cited by 541
Self-citationPolak, P., Kim, J., Braunstein, L. Z., Karlic, R., Haradhavala, N. J., Tiao, G., Rosebrock, D., Livitz, D., Kübler, K., Mouw, K. W., et al. (2017) · Nature Genetics · doi:10.1038/ng.3934 · Cited by 531
Metadata
- Authors
- Hyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P., Baselga, J., Berger, M. F., & Ladanyi, M.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 20
- Issue
- 12
- Pages
- 1422-1428
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1192724814
- Cited by
- 148
- References
- 13
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. https://app.cochat.ai/papers/10.1016/j.drudis.2015.08.005
- The paper
- Hyman, D. M., Solit, D. B., Arcila, M. E., Cheng, D. T., Sabbatini, P., Baselga, J., Berger, M. F., & Ladanyi, M. (2015). Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2015.08.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.